Bullish Case: After a 23.5% ninety-day flush to $56.18, Helium's term structure shows steep contango (near ~30% rising to ~52% by May 2027) versus market IV of 64.9% at 11/21 — Helium sees near-term volatility as overpriced, favoring mean reversion. Call volume runs 41% above puts, bullish risk exceeds bearish by 27%, and the Jan-2027 65C/Feb 70C carry 0.28–0.33 deltas with heavy flow. The Q4 FDA submission window plus payer-coverage expansion and Rahim's late-stage-biotech acquisition narrative could snap price back toward the $62–68 IV-smile trough.

Bearish Case: Every prior bullish band ($68–72, $72–79, $62–72 Q4 recovery) has been overrun as CYTK fell through them — a pattern of systematically missed downside timing. Deep-put IVs of 116–310% and the 11/20 55P (IV 58.6, delta -0.39, 375 contracts) show the market pricing continued downside. The return surface's wide dispersion means moderate bounces aren't modal, BMS patent risk, 12.7x book, and the AI forecast's -0.2 realized correlation (+1.98% call) argue against fade-trusting the bounce.

Potential Outcomes: 1) 40% — Stabilization/bounce: $56–63 mean-reversion into January; falsified by a close below $52.
2) 30% — Downside continuation: $45–54 as FDA-submission timing or uptake concerns deepen; confirmed by put-wing IV steepening further.
3) 20% — Bullish rerate: $64–70 on submission confirmation or payer news; watch Jan 65C flow.
4) 10% — Tail shock (>±25%) from regulatory/safety/BMS escalation; deep wings price 150%+ IV.

November 11, 2026